Candel Therapeutics Inc.

4.68
-0.57 (-10.86%)
At close: Apr 04, 2025, 2:44 PM
-10.86%
Bid 4.68
Market Cap 221.06M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.74
PE Ratio (ttm) -2.69
Forward PE -7.36
Analyst Buy
Ask 4.69
Volume 948,160
Avg. Volume (20D) 1,225,637
Open 5.09
Previous Close 5.25
Day's Range 4.67 - 5.12
52-Week Range 3.79 - 14.60
Beta -0.94

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of hi...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2021
Employees 38
Stock Exchange NASDAQ
Ticker Symbol CADL
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for CADL stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 370.09% from the latest price.

Stock Forecasts
1 week ago
-7.33%
Candel Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription
1 month ago
-23.45%
Candel Therapeutics shares are trading lower after the company reported phase 2 trial results.